Rapid and reliable manufacturing of SQZ® Cell Therapy Candidates in under 24 Hours
Breaking through manufacturing barriers is a critical focus area for the cell therapy industry. By eliminating the need for viral vectors, electrical fields and multi-day cell expansion procedures, our SQZ® cell therapy candidates are designed to be manufactured in under 24 hours. By continuing to innovate on cell therapy manufacturing processes, we aim to potentially achieve same-day treatment of patients in the future.
Flexible Cell Engineering at Clinical Scale
Our GMP-compliant Cell Squeeze® system, used across our ongoing clinical trials, can achieve efficient, high-viability engineering at a rate of over 10 billion cells / minute for patient dose production.
Current SQZ® Cell Therapy Production
Time to Treatment
No Viral Vectors
used in manufacturing process
Cell therapy manufacturing demonstrated
Lower Cost per Dose
projected compared to marketed cell therapy products
SQZ® Point-of-Care Manufacturing System
Integrated, automated cell therapy manufacturing with the SQZ® Point-of-Care system
The SQZ® Point-of-Care (POC) system is designed to integrate our differentiated, proprietary Cell Squeeze® technology with end-to-end, closed process automation with the goal of reducing the time, cost and complexity of cell therapy manufacturing.
SQZ® POC has the potential to broaden accessibility of cell therapies by addressing the primary cost and resource drivers of manufacturing
Potential to eliminate clean room
Future decentralized production at or near treatment centers without a clean room
Accelerated Production Timelines
Reduced production timelines, inclusive of manufacturing, QC, and release testing
Removal of Manual Steps
Substantial removal of manual steps to improve process reproducibility
Potential for meaningful reduction in operators and operator hours
Learn more about our manufacturing
High-performance, scaled engineering with the Cell Squeeze® system. Read more
Rapid, reliable manufacturing in <24 hours of SQZ® APC candidate in Phase 1/2 trial. Read more
Automated manufacturing of a SQZ® red blood cell product candidate in under 6 hours with the Point-of-Care system. Read more
Collaborate with us to advance cell therapy development and manufacturing
Interested in applying the Cell Squeeze® technology to facilitate next-generation cell therapy development? Fill out the form below to connect about our Manufacturing Access Program.